Active Movers of Yesterday: Southwest Airlines Co (NYSE:LUV), PMC-Sierra Inc (NASDAQ:PMCS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

On Friday, Shares of Southwest Airlines Co (NYSE:LUV), lost -1.65% to $40.56.

Southwest Airlines Co., invites you to listen to a live webcast of its third quarter 2015 financial results on Thursday, October 22, 2015 at 12:30 PM Eastern Time.

Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft.

Shares of PMC-Sierra Inc (NASDAQ:PMCS), declined -0.39% to $10.24, during its last trading session.

PMC-Sierra, declared the Company will release its third quarter earnings results on Monday, October 26, 2015, following the close of the U.S. stock market.

PMC-Sierra, Inc. designs, develops, markets, and supports semiconductor solutions for communications network infrastructure equipment worldwide. Its semiconductor devices enable networking equipment primarily in three markets, counting storage, optical, and mobile networks.

Finally, Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ended its last trade with 5.13% gain, and closed at $177.54.

Valeant Pharmaceuticals International, declared that it has accomplished the formerly declared acquisition of Synergetics USA , Inc. (Synergetics). Synergetics is a leading supplier of precision surgical devices. Synergetics primary focus is on the surgical disciplines of ophthalmology and neurosurgery.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.


This article is published by The content included in this article is just for informational purposes only. takes sensible consideration to ensure that the data given in this article is up to date and accurate. The news, prices, opinions, research, analysis, and other information published in this article are obtained from sources believed to be reliable.

Neither nor any of partners make any representation or guarantee as to the fulfillment or precision of the information contained in this article.

Investors must consult their own additional due diligence with any potential investment or highlighted company before making any decision on behalf of information offered by

Information contained in this article may contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long-term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.

About Travis Garlick 1791 Articles
Been writing about and trading stocks since 2013. Manage a group of micro-cap investors on Facebook with over 15,000 members. Turned $8,500 into 185k the first year I started trading stocks and haven't looked back.